There was an error in the original publication [], A sentence was accidentally written in a way that it could possibly imply that resmetirom has been tested on children:
“In addition to adult MASH patients, resmetirom has shown potential for treating MASLD in children with obesity, with encouraging results in improving steatohepatitis and fibrosis in up to 36% and 27% of patients, respectively [49].”
A correction has been made to Paragraph 4 of the Section 2.4. Comprehensive Phase 3 Trials:
“In addition to adult MASH patients, resmetirom could show potential for treating MASLD in children with obesity, with encouraging results in improving steatohepatitis and fibrosis in up to 36% and 27% of 29 adult patients, respectively. However, there are currently no ongoing studies evaluating the effect of resmetirom in obese children with MASLD [49].
Despite promising results regarding the administration of resmetirom in adult patients with MASLD/MASH, there is a lack of clinical trials on its long-term safety in these patients. Also, absence of long-term studies on the progression of MASLD in children and adolescents remains an obstacle in developing pharmacotherapeutic approaches to pediatric MASLD. This highlights the need for further research assessing the long-term safety of resmetirom in adult patients, as well as the potential use of resmetirom in treating pediatric MASLD.”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Knezović, E.; Hefer, M.; Blažanović, S.; Petrović, A.; Tomičić, V.; Srb, N.; Kirner, D.; Smolić, R.; Smolić, M. Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom. Curr. Issues Mol. Biol. 2025, 47, 154. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).